🧾 What This Document Is

This is a prospectus filing with the SEC. Its main job is to let certain investors ("selling stockholders") legally resell up to 2,777,781 shares of Tempest Therapeutics' common stock to the public. Think of it as a "resale permit" for these specific shares.

👉 The key point: Tempest Therapeutics itself will NOT receive any money from these sales. The cash goes directly to the selling shareholders who already own the shares or warrants.

🏢 What The Company Does

In simple terms, Tempest Therapeutics (TPST) is a clinical-stage biotech company. This means they are developing new medicines but don't have any products on the market yet. They spend money on research and trials, hoping to one day sell treatments.

Their pipeline has two main types of programs:

• Cell Therapies (CAR-T): Advanced treatments where a patient's own immune cells are re-engineered to fight cancer. Their lead candidate here is TPST-2003, targeting a blood cancer called multiple myeloma.
• Small Molecules: More traditional drug compounds. Their candidate amezalpat is for liver cancer, and TPST-1495 is for a rare intestinal condition.

💰 The Share Details (The Financial Mechanics)

The 2.7+ million shares being registered aren't all plain common stock. They come from a mix of instruments, which is common in complex financing deals:

• 462,964 are regular shares.
• 925,927 shares come from exercising "Series A Warrants."
• 925,927 shares come from exercising "Series B Warrants."
• 462,963 shares come from exercising "Pre-Funded Warrants."

👉 These shares were all acquired by the selling investors in a Private Placement deal on March 20, 2026. This prospectus is the follow-up paperwork needed to allow those investors to eventually sell their shares on the open market.

🚀 The Deal That Started It All (Private Placement)

The selling shareholders originally got these shares and warrants by participating in a Private Investment in Public Equity (PIPE) deal. This is a common way for public biotech companies to raise quick cash from institutional investors.

Why it matters: This filing isn't about raising new money. It's about giving the investors from that March 2026 deal an "exit door" to sell their shares later. The company's stock (TPST) trades on the Nasdaq, and at the time of this filing, it was priced at $1.56 per share.

📦 The Cash Position & "Going Concern" Risk

This is the most critical context from the filing. The company's financial statements, referenced in the document, contain a "going concern" note. This is a major red flag from auditors, signaling substantial doubt about the company's ability to stay in business over the next year without securing more funding.

👉 The company's current cash is likely very low. They are relying on future financing or a partnership (like for their amezalpat drug) to fund operations and continue clinical trials. This risk is explicitly listed for investors to consider.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

• Diverse Pipeline: They have both cell therapy and small molecule programs in clinical stages.
• Strategic Assets: Their assets, like the Phase 3-ready amezalpat, could be attractive for partnership deals.
• External Funding: One trial (TPST-1495) is set to be funded by the National Cancer Institute, saving company cash.

⚠️ Major Risks:

• Going Concern: Auditors doubt their ability to continue operating. This is the #1 risk.
• Clinical & Regulatory Risk: All value depends on unproven drug candidates successfully passing trials and getting approved. Failure is common.
• Dilution: This very filing allows nearly 2.8 million new shares to be sold, which can increase the share count and potentially lower the stock price for existing investors.
• Need for Capital: They need to raise more money soon, likely through another share offering (which would further dilute ownership) or a partnership (where they might give up rights to future profits).

🧠 The Analogy

Imagine a biotech company (Tempest) is a house they're trying to build. The Private Placement (PIPE) was like selling future sections of the house to investors for quick cash to buy building materials. This 424B3 filing is just giving those investors a permit to eventually sell their "future sections" to other people. It doesn't provide any new cash to finish building the house, and the construction company is warning they might run out of money before the roof is on.

🧩 Final Takeaway

This filing is a routine, regulatory "resale" document for past investors. It doesn't directly impact Tempest's operations or cash. The real story is the company's precarious financial "going concern" status and its urgent need to fund its promising but high-risk pipeline before its cash runs out.